Sugi Predict

Sugi Predict / Targets / CCNB2

CCNB2

G2/mitotic-specific cyclin-B2 · O95067 · CCNB2 on Sugi Atlas →

69,978 patent compounds predicted against CCNB2, 46,948 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL490814 SCHEMBL490814 1.00 20/20
SCHEMBL490541 SCHEMBL490541 0.72 20/20
SCHEMBL490777 SCHEMBL490777 0.72 20/20
Kenpaullone Kenpaullone (SCHEMBL79889) 1.00 19/20
SCHEMBL490933 SCHEMBL490933 1.00 19/20
SCHEMBL491100 SCHEMBL491100 1.00 19/20
SCHEMBL489971 SCHEMBL489971 1.00 18/20
SCHEMBL490489 SCHEMBL490489 1.00 18/20
SCHEMBL490667 SCHEMBL490667 1.00 18/20
SCHEMBL490671 SCHEMBL490671 1.00 18/20
SCHEMBL490775 SCHEMBL490775 1.00 18/20
SCHEMBL490811 SCHEMBL490811 1.00 18/20
SCHEMBL491124 SCHEMBL491124 1.00 18/20
Bromide Bromide (SCHEMBL490969) 0.97 18/20
SCHEMBL490088 SCHEMBL490088 0.63 18/20
SCHEMBL491139 SCHEMBL491139 0.59 18/20
Aloisine Aloisine (SCHEMBL79714) 1.00 17/20
Aloisine A Aloisine A (SCHEMBL80147) 1.00 17/20
SCHEMBL490379 SCHEMBL490379 1.00 17/20
SCHEMBL490878 SCHEMBL490878 1.00 17/20

Clinical trials — most relevant to CCNB2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients PHASE3UNKNOWN
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer PHASE2/PHASE3NOT_YET_RECRUITING
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease PHASE3RECRUITING
Abemaciclib With or Without Atezolizumab for mCRPC PHASE2COMPLETED
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage PHASE2RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer PHASE2RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma PHASE2COMPLETED
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer PHASE2COMPLETED
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer PHASE2WITHDRAWN
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Study of AVZO-021 in Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. PHASE1/PHASE2COMPLETED
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer PHASE2COMPLETED
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas PHASE2RECRUITING
Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification PHASE2COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms PHASE1COMPLETED
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors PHASE1RECRUITING
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas PHASE1COMPLETED
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers PHASE1COMPLETED
Tamoxifen in Patients With Oesophageal Cancer PHASE1UNKNOWN
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma PHASE1COMPLETED
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy nanUNKNOWN
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CCNB2 binder may also engage these)

ProteinNameSimilarity
Q4R7A8 — 1.000 Q4R7A8 →
P37883 — 1.000 P37883 →
P30276 — 1.000 P30276 →
Q60FY0 — 0.995 Q60FY0 →
O77689 — 0.995 O77689 →
P29332 — 0.993 P29332 →
Q92162 — 0.991 Q92162 →
Q60FX9 — 0.989 Q60FX9 →
O93229 — 0.989 O93229 →
P13350 — 0.987 P13350 →
P13351 — 0.986 P13351 →
Q9IBG1 — 0.978 Q9IBG1 →
Q9DGA0 — 0.977 Q9DGA0 →
Q9DG96 — 0.975 Q9DG96 →
Q9DGA3 — 0.973 Q9DGA3 →
Q9DG99 — 0.971 Q9DG99 →
Q9DGA4 — 0.970 Q9DGA4 →
Q9DG97 — 0.967 Q9DG97 →
Q9IBG0 — 0.966 Q9IBG0 →
P24860 — 0.962 P24860 →
P37882 — 0.960 P37882 →
P30277 — 0.959 P30277 →
P15206 — 0.958 P15206 →
Q9SA32 — 0.958 Q9SA32 →
Q1LZG6 — 0.955 Q1LZG6 →
Q01066 — 0.952 Q01066 →
F1QMB9 — 0.950 F1QMB9 →
Q61481 — 0.945 Q61481 →
P14100 — 0.944 P14100 →
Q64395 — 0.944 Q64395 →